Patent ID: 7452883

Claim:
A method for inhibiting the formation of advanced glycosylation end products (AGE) in a patient that has and is being treated for atherosclerosis and/or Alzheimer's disease, comprising: administering to said patient in need thereof an effective amount of a compound of formula (I) in which: R1 and R2 are chosen independently from the groups: —H, —(C 1 -C 20 )alkyl, wherein R3 and R4 are chosen independently from the groups: —H, —(C 1 -C 20 )alkyl, —(C 2 -C 20 )alkenyl, R3 and R4 can form with the nitrogen atom an n-membered ring (n between 3 and 8) optionally comprising one or more heteroatoms chosen from N, O, S, R5 and R6 are chosen independently from the groups: H, (C 1 -C 20 )alkyl optionally substituted with hydroxyl, (C 3 -C 8 )cycloalkyl optionally substituted with (C 6 -C 14 )aryl (C 1 -C 5 )alkoxy, (C 3 -C 8 )heterocycloalkyl carrying one or more heteroatoms chosen from N, O, S, (C 6 -C 14 )aryl optionally substituted with hydroxyl, (C 1 -C 13 )heteroaryl carrying one or more heteroatoms chosen from N, O, S, (C 6 C 14 )aryl (C 1 -C 5 )alkyl, wherein R5 and R6 can form with the carbon atom to which they are attached an m-membered ring (m between 3 and 8) optionally comprising one or more heteroatoms chosen from N, O, S and being capable of being substituted with hydroxyl, (C 1 -C 5 )alkyl, (C 6 -C 14 )aryl (C 1 -C 5 )alkoxy, wherein when R1 and R2 represent a hydrogen, or R3 and R4 represent a hydrogen, then R3 and R4 or R1 and R2 are defined as above with the exception of hydrogen, or a form selected from the group consisting of tautomeric, enantiomeric, diastereoisomeric and epimeric or the pharmaceutically acceptable salt thereof.